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SUMMARY
Forms of dyslipidemia are very common in individuals
affected by polycystic ovary syndrome (PCOS), but in addition
to plasmatic lipids, it is necessary to evaluate the alterations in
the atherogenic lipoproteins (Lp) and apolipoproteins (apo).
In our study we measured the concentrations of apoB,
Lp(a) and low density lipoproteins (LDL) in 42 patients with
PCOS (age: 28 +/- 7 years, body mass index: 27 +/- 5 kg/m_)
and 37 healthy women (of the same age and body mass index).
M e t h o d s: values of Lp(a) >30 mg/dl were considered
high, whereas for apoB, values >100 g/l were considered high.
Results: the patients with PCOS showed an increase in
triglycerides (p=0.0011) and low levels of high density lipopro-
teins (HDL) (p=0.0131), but the total cholesterol and the LDLs
were not significantly different to those of the control group.
High levels of Lp(a) were found in 24% of the individuals with
PCOS, and a smaller number showed high levels of apoB
(14%).
This analysis shows that the concentrations of Lp(a) are
only correlated to the HDLlevels (r =0.378, p= 0.0431). 36%
of the patients with PCOS with normal levels of plasmatic
lipids show high levels of Lp(a) and apoB, and small and dense
LDLs.
Conclusions: alterations in the plasmatic lipids are pre-
sent in 1/3 of the women affected by PCOS. More research is
necessary to better understand the mechanisms responsible to
reduce the risk of cardiovascular problems in young women
with polycystic ovary syndrome.
Key words:Polycystic ovary syndrome, body mass index,
atherogenic lipoproteins
RIASSUNTO
Le forme di dislipidemia sono molto comuni nei soggetti
affetti da sindrome dell’ovaio policistico(PCOS) ma, oltre ai
lipidi plasmatici, è necessario valutare le alterazioni delle lipo-
roteine aterogene (Lp) e le apolipoproteine (apo).
Nel nostro studio, abbiamo misurato le concentrazioni di
apoB, Lp(a) e delle lipoproteine a bassa densità (LDL) in 42
pazienti con PCOS (età: 28 ± 7 anni, body mass index: 27 ± 5
kg ⁄ m2 ) e 37 donne sane (di pari età e body mass index).
M e t o d i: Sono stati considerati elevati i valori di Lp(a)
>30 mg/dl, mentre per apoB, valori >100 g/l.
Risultati: le pazienti con PCOS mostravano un aumento
dei t igliceridi (p=0.0011) e bassi valori di lipoporteine ad alta
densità (HDL) (p=0.0131), mentre il colesterolo totale e le
LDL non differivano in modo significativo rispetto ai controlli.
Elevati valori di Lp(a) furono trovati nel 24% dei sogget-
ti c n PCOS, mentre una minoranza presentava elevati livelli
di apoB (14%). Tale analisi rivela che le concentrazioni di
Lp( ) sono correlate solo con i livelli di HDL(r =0.378, p=
0.0431). Il 36% delle pazienti con PCOS con normali valori
dei lipidi plasmatici presentano elevati livelli di Lp(a), apoB e
LDL piccole e dense.
C o n c l u s i o n i: le alterazioni dei lipidi plasmatici sono
 senti in 1/3 delle donne affette da PCOS. Sono necessari
ulteriori studi per conoscere meglio i meccanismi responsabili
al fin di ridurre il rischio card i o v a s c o l a re in giovani donne
c n si drome dell’ovaio policistico.
Parole chiave: Sindrome dell’ovaio policistico, indice di massa
corporea, lipoproteine aterogene
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Introduction
Polycystic ovary syndrome (PCOS) is the most
frequent form of endocrinopathy found in women;
in fact more than 10% of those of reproductive age
are affected. Despite it being well-known that PCOS
is linked to reproductive pathologies and an increa-
sed risk of endometrial cancer, diagnosis of PCOS is
of great interest for the cardiovascular risks entailed,
a consistent datum especially in some geographical
areas and ethnic groups(1, 2).
In women with PCOS, as opposed to women
with normal cycles, insulin resistance, android obe-
sity and hypertension can be found(3). Severe indices
of arteriosclerosis, clinical and subclinical, have
b en found in women with PCOS( 4 - 8 ); dyslipidemia
is very common and is characterised by low chole-
sterol values and hypertriglyceridemia(1, 2).
Over the last few years, several studies have
suggested how, among the plasma lipids, diff e r e n t
li oproteins (Lp) and abnormal apoliproproteins
increase the risk of cardiovascular pathology.
These alterations include high levels of Lp(a),
as well as high levels of apoB; at the moment the
exact incidence of these forms of dyslipidemia in
women with PCOS is not yet known and this limits
the usefulness of the information.
In our study we included 42 patients of
Caucasian origin, from the Mediterranean, affected
by PCOS and 37 healthy women chosen by age and
body mass index with the aim of evaluating: 
a) whether the levels of Lp(a) or apoB chan-
ged in subjects with PCOS compared to control; 
b) whether these levels could be correlated
with the levels of lipids circulating in the plasma or
with the presence of arteriogenic lipoproteins such
as small dense low density lipoproteins (LDL); 
c) whether the patients with PCOS with nor-
mal levels of lipids in the plasma might show the
presence of abnormal arteriogenic lipids (e.g. high
levels of Lp(a), apoB or small dense LDL).
Methods and materials
42 women of reproductive age affected by
PCOS were enlisted at the Department of Clinical
Medicine and Emerging Pathologies, Clinical of
Internal Medicine, University of Palermo.
Diagnosis of PCOS was based on clinical and
biological evidence of hyperandrogenism associa-
ted with chronic anovulation and/or ultrasound
demonstration of a polycystic ovary(10).
Anovulation was defined as serum levels of
progesterone lower than 3 ng/ml (< 9.54 nmol/L).
In patients with regular cycles, at least two conse-
cutive cycles were studied and the ascertainment of
low serum levels of progesterone (<3ng/ml) in both
cycles were indicative of anovulation. 
Patients with anovulatory( 3 1 ) and ovulatory( 11 )
PCOS were thus identified(7, 11). 
The presence of ovarian polycystosis was
investigated through suprapubic and transvaginal
ecographic investigation. The criteria for indicating
the presence of polycystic ovaries was based on the
confirmation of enlarged ovaries and/or the presen-
ce of at least 12 follicular cysts with a diameter of
2-9 mm( 1 3 ). All the patients in the study showed
these characteristics. 
The study included a medical check-up and
biochemical surveys. 
The procedures adopted were in accordance
with the Helsinki Declaration of 1975 as revised in
1983 and the study was approved by the local ethics
council. 
All subjects gave their informed consent to
participate in the study. 
The patients, after undergoing a medical exa-
mination, were asked to fill in a questionnaire on
personal and medical items, including age, past
medical history and any use of medications.
Exclusion criteria included renal or hepatic diseases
capable of modifying the plasma concentration of
lipoproteins or the use of hypolipemizing medica-
tion. No patient had type 2 diabetes mellitus or was
taking medication from at least three months before
the study. In the control group there were 37
healthy women, matched for age and body weight
using the same exclusion criteria described above.
Control subjects were women with regular
menstrual cycles and normal hormonal values. The
following were recorded: weight, height, BMI and
waist circumference for both groups. Hypertension
(systolic or diastolic, respectively, ‡ 140mmHg or ‡
90 mmHg also in treatment with hypertensive
medication), diabetes (fasting plasma glucose con-
centration greater than 126mg/dl) and smoking
were among the cardiovascular risk factors taken
i to consideration.
Laboratory tests
The cholesterol and triglyceride plasma con-
ce trations were measured on a Roche (Roche
Diagnostics, Rotkreuz, Switzerland) commercial
m dular system using reagents with a variation
c efficient of 2.3% - 2.4% respectively. The evels
of HDLcholesterol, Lp(a) and apoB were measured
with a Roche Integra 800 analyzer, using commer-
cial ests (Roche Diagnostic), with a variation of
4.1%, 2.3% and 1.2% respectively. The LDLvalues
were calculated using the Friedeward formula.
Insulinemia and any insulin resistance were calcu-
lated by different methods, including fasting insuli-
nemi , the HOMA(homeostasis model assessment)
method, and QUICKI (quantitative insulin sensiti-
vity check index). 
The estimate for insulin resistance through the
“ H O M Ascore” method was calculated using the
following formula: serum levels of fasting insulin
(µU/ml) x plasma levels of fasting glucose
(mmol/l)/22.5 (14). The QUICKI method was deri-
ved from the inverse calculation of the sum of the
logarithmic values of fasting insulin and glucose
(15). Low density lipoproteins and subclasses were
evaluated by electrophoresis of the plasma at 10-
14°C with polyacrylamide gel.
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Initially the gels underwent electrophoresis for
24 hours at 124 Vin a tris borate buffer (pH 8.3)
(16). They were then fixed and coloured in a solution
of red oil in 60% ethanol at 55°C; they were subse-
quently exposed to a light source and photographed
using a Fujifilm LAS 3000 Luminescent Image
A n a l y z e r. The migration distance for each absorban-
ce peak and the molecular diameter corresponding to
each peak were determined; everything was calcula-
ted using a calibration curve generated by the distan-
ce migration of standard particles with known dia-
m e t e r, which included carboxylated latex beads
(Duke Scientific, Palo Alto, CA), thyroglobulin and
apoferritin (HMWStd, Pharmavia, Piscataway, N),
with molecular diameters of 380, 170 e 122 Å,
r e s p e c t i v e l y. Lp calibration was also carried out after
the particle size had been determined.
L D L percentage subclass distribution of total
LDL, was calculated as previously described. T h e
total of small dense LDLwas obtained by the sum
of the single values of LDLIII and LDLI V s u b-
classes (LDL-IIIA+ LDL-IIIB + LDL-IVA + LDL-
IVB).
To evaluate whether the plasma lipids or Lp
were abnormal in women with PCOS, we conside-
red the following cutoffs in accordance with the
mor  recent international guidelines(9,17): high trigly-
cerides if > 1.7 mmol/l, low cholesterol if < 4.1
mmol/l, high Lp (a) values if > 30 mg/dl, high apoB
if > 100 g/l. Higher levels by 2DS of small dense
LDL were found in the patients with PCOS compa-
red to the controls.
Results
The patients with PCOS and the control group
had a similar BMI, in compliance with the inclusion
criteria. Nevertheless, the abdomen circumference
was greater in women with PCOS compared to the
healthy women (91+/- 13 v. 80+/- 6 cm, p<0.01).
As shown in table 2, patients with PCOS showed an
increase in triglycerides and low total levels of cho-
lesterol, whilst total cholesterol and LDLdid not
differ significantly compared to the controls.
Women with PCOS also showed an increase in
insulin values and insulin resistance, as shown by
HOMA and QUICKI (all p=0.0001). The prevalen-
ce of high levels of triglycerides and LDLcholeste-
rol in women with PCOS was low (9% and 14%
respectively) and there were no significant differen-
ces compared to the values found in the controls.
Low levels of HDLcholesterol were found in 33%
of women with PCOS, against 14% of the controls
(p=0.0460). We also found that the women with
PCOS showed small size (p=0.0005) LDL(data not
shown) because of a reduction in larger particles
with a concomitant increase of the medium and
small subspecies (LDL-IIB, -IIIA, -IIIB e –IVA ) ;
thus, the total levels of dense small LDLw e r e
strongly increased in the women with PCOS com-
pared to the controls (40± 8% vs. 31 ± 6%, p<
0.0001). 
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PCOS(n=42)Controls(n=37) p=
TC (mmol/l) 4.7 ± 0.9 4.3 ± 1.2 ns
TG (mmol/l) 1.0 ± 0.5 0.6 ± 0.4 0.001
HDL (mmol/l) 1.2 ± 0.3 1.5 ± 0.7 0.013
LDL (mmol/l) 3.1 ± 1.1 2.7 ± 1.6 ns
­ TG (>1.7
mmol/l), (%)
9 3 ns
¯ HDL
(<1.1mmol/l)(%)
33 14 0.046
­ LDL (>4.1
mmol/l)(%)
14 8 ns
Insulina (µU/ml) 13 ± 5 7 ± 2 <0.0001
HOMA 2.8 ± 1.1 1.1 ± 0.3 <0.0001
QUICKI 0.33 ± 0.02 0.37± 0.01 <0.0001
PCOS(n=2)
Controls
(n=37)
p=
Età (anni) 28 ± 7 31 ± 2 ns
BMI (kg/m2) 27 ± 5 26 ± 4 ns
Hypertension
(%)
2 0 ns
Diabetes (%) 0 0 ns
Smoke (%) 16 19 ns
GCV(%) 7 11 ns
Table 1: caratteristiche cliniche e dati laboratoristici
delle pazienti affette da PCOS e del gruppo controllo.
PCOS (n=42)Controlli (n=37)p=
Lp(a) (mg/dl) 24 ± 26 5.2 ± 5.1 0.0143
Log Lp(a) 1.12 ± 0.53 0.57 ± 0.35 0.0014
­ LP(a) (> 30 mg/dl)
(%)
24 0
<
0.0001
ApoB (g/l) 79 ± 24 81 ± 44 ns
­ apoB (<100 g/l)
(%)
14 15 ns
Table 2: Levels of di Lipoprotein(a) and of ApoB 
The women with PCOS also had high concen-
trations of Lp(a), taken both as absolute values
(p=0.0143) and after logarithmic transformation
(p=0.0014); conversely no difference was found for
the apoB levels. High levels of Lp(a) were found in
_ of the women with PCOS (24%), whilst high
levels of apoB were relatively scarce (14%).
We also found a normal lipids profile in 25
patients with PCOS, but further analysis showed
the presence of “hidden” altered pro-arteriogenic
lipoproteins in 9 subjects (e.g. high levels of Lp(a)
or dense small LDL).
Discussion
Cardiovascular disease is the major cause of
death in the world for both sexes, but women are
hormonally protected before the menopause and the
onset of cardiovascular disease is normally delayed
by 10-15 years compared to men( 9 , 1 9 ); n vertheless,
young women may show an increased cardiovascu-
lar risk when affected by PCOS( 2 ). The reason for
the increase in the risk is not yet clear; hyperandro-
genism has not yet been recognised as a risk factor
for cardiovascular disease and studies on pre- and
post-menopausal women do not show a clear asso-
ciation between hyperandrogenism and the risk of
future cardiovascular events(21). 
C o n v e r s e l y, altered metabolic conditions like
insulin resistance and dyslipidemia seem to have an
important role on the risk of cardiovascular patho-
logy in women with PCOS(22), but it is still unknown
to what degree dyslipidemia may contribute to this
risk increase. Lipid alterations are common in
women with PCOS( 1 , 2 , 7 ), but are heavily influenced
by other factors like diet and physical exercise( 2 3 ).
As we have shown in our population of women
with PCOS( 7 , 1 8 , 2 3 ), the triglyceride levels are within
the norm, although significantly increased compa-
red to the controls. Also high levels of LDLchole-
sterol were not common (14%), whereas low con-
centrations of HDLcholesterol were found in a
third of the subjects (33%).
In the last few years several studies have sug-
gested that, as well as plasma lipids, different alte-
rations of Lp and apoB significantly increase the
cardiovascular risk(9, 24). High LDLlevels represent
the most common lipid alteration (44%) in women
with PCOS. In order to evaluate if there are other
lipids promoting arteriosclerosis in women with
PCOS, we also evaluated the Lp(a) and apoB con-
centrations.
ApoB is the main structural component of
LDL and its evaluation represents a more accurate
measurement of the relative number of LDLparti-
cles compared to the more common measurement
of LDLcholesterol(9).ApoB is a true indicator of the
number of particles promoting arteriosclerosis. We
found no difference in apoB levels between women
with PCOS and the controls, and their high concen-
tration was not common (14%). 
These results are consistent with those found
recently in a study of subjects with PCOS in
H o l l a n d( 2 6 ), but differ from those found in Tu r k is h
adolescents, not obese, with PCOS where the apoB
levels were significantly increased compared to the
controls. Probably, genetic and environmental fac-
tors may determine different lipid patterns(23) nd, on
the basis of data not available, the determination of
poB l vels is not indicated in women with PCOS.
Lipoprotein(a) is a heterogeneous class of
lipoproteins made up of an apo(a) molecule linked
to a apoB-100 and a lipid. Lp(a) is metabolically
distinct from LDLand its levels are determined
genetically, with its concentration remaining stable
throughout the life of a subject(28). High Lp(a) levels
represent an independent risk factor for cardiova-
scular events, linked to an increased risk of myocar-
dium infarction, stroke and coronary heart disease
(28-30). In our study we have shown greater concentra-
tions of Lp(a) in women with PCOS, both in abso-
lut values and after logarithmic transformation;
furthermore, high levels of Lp(a) were found in
about a quarter of the subjects (24%).
Even if the questions relating to the measure-
ment of Lp(a) cannot be carried out in clinical prac-
tice, we have used the maximum commonly accep-
ted limit to define those levels( 3 3 ). It has also been
recently demonstrated in large scale prospective stu-
dies that the concentrations of Lp(a) are strong pre-
dictors of cardiac disease( 3 4 ). It is interesting to note
that said association of Lp(a) and coronary disease
is independent of the insulin resistance factor. 
The simultaneous increase of Lp(a) and LDL
could increase the cardiovascular risk with synergic
 fect. We also found in this study that these two
lipoprotein variables are not significantly correlated
and that Lp(a) is not correlated with levels of insu-
lin or insulin resistance, suggesting that dyslipide-
mia can stem from different metabolic mechanisms.
A  the moment it is not known to what degree these
d i ferent forms of dyslipidemia may contribute to
increasing this cardiovascular risk in PCOS and
future prospective studies are needed. 
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Our study also demonstrates that more than a
third of the patients with PCOS with a normal lipid
profile have altered lipids that can cause arterioscle-
rosis (high levels of Lp(a) or LDLare included). It
was recently shown that Lp(a) and LDLare correla-
ted with severe pictures of coronary heart disease(37)
and this can be at least in part because of their com-
bined effects on haemostasis( 3 8 ). Moon et al.(37) h a v e
found a strong correlation between LDLa d Lp(a)
in patients with stenosis of the coronary arteries and
this can be linked to the role of Lp(a) as a vehicle
for pro-inflammatory products(39, 40), which in the last
analysis led to an increase of oxidized LDLlevels
in the coronary arteries(41). 
At the moment it is not known whether thera-
peutic modulation of these lipids can significantly
reduce the cardiovascular risk. 
Management of dyslipidemia in PCOS is still
under debate, weight reduction and greater physical
activity are the first level of therapy, whilst medica-
tion that reduces the cholesterol levels, including
statins, nicotinic acid and fibrates, are only used in
patients with severe dyslipidemia(42). Or l hypogly-
cemizing drugs are also effective agents and combi-
ned therapy remains an option; in particular the
combination of pioglitazone + metformin could be
beneficial(42). It is well known that statins are rather
ineffective on Lp(a) concentrations, whereas nicoti-
nic acid markedly reduces both Lp(a) an LDL
levels(44). No data on metformin is available, which
demonstrates the contrasting effects on modulation
of Lp(a) levels in women with PCOS(45,46). 
We must thus wait for the results from prospec-
tive studies to know whether hypolipemizing and/or
insulin sensitizing drugs are capable of reducing car-
diovascular risk in women with PCOS; these, in the
short term, act by reducing the dyslipidemia promo-
ting arteriosclerosis (reduction of carotid myointi-
mal thickness) and, in the long term (reduction of
cardiovascular morbidity and mortality). 
In conclusion, this study was conducted to
underline the presence of artherogenic dyslipidemia
in women with PCOS in the Mediterranean basin.
We found that our patients with PCOS show increa-
sed concentrations of Lp(a), whereas the concentra-
tions of apoB are unaltered. These changes seem in
part to be linked to insulin resistance, but it cannot be
excluded that other responsible mechanisms may be
identified in the near future. In particular, the Lp(a)
measurement in women with PCOS could facilitate
the evaluation of cardiovascular risk and adapt the
treatment on the basis of objectives to be reached.
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